SooHoo Nelson F, Kominski Gerald
Department of Orthopaedic Surgery, University of California at Los Angeles, 10833 Le Conte Avenue, Room 76-143 CHS, Los Angeles, CA 90095.
J Bone Joint Surg Am. 2004 Nov;86(11):2446-55. doi: 10.2106/00004623-200411000-00014.
There is renewed interest in total ankle arthroplasty as an alternative to ankle fusion in the treatment of end-stage ankle arthritis. Despite a lack of long-term data on the clinical outcomes associated with these implants, the use of ankle arthroplasty is expanding. The purpose of this cost-effectiveness analysis was to evaluate whether the currently available literature justifies the emerging use of total ankle arthroplasty. This study also identifies thresholds for the durability and function of ankle prostheses that, if met, would support more widespread dissemination of this new technology.
A decision model was created for the treatment of ankle arthritis. The literature was reviewed to identify possible outcomes and their probabilities following ankle fusion and ankle arthroplasty. Each outcome was weighted for quality of life with use of a utility factor, and effectiveness was expressed in units of quality-adjusted life years. Gross costs were estimated from Medicare charge and reimbursement data for the relevant codes. The effect of the uncertainty of estimates of costs and effectiveness was assessed with sensitivity analysis.
The reference case of our model assumed a ten-year duration of survival of the prosthesis, resulting in an incremental cost-effectiveness ratio for ankle arthroplasty of $18,419 per quality-adjusted life year gained. This reflects a gain of 0.52 quality-adjusted life years at a cost of $9578 when ankle arthroplasty is chosen over fusion. This ratio compares favorably with the cost-effectiveness of other medical and surgical interventions. Sensitivity analysis determined that the cost per quality-adjusted life year gained with ankle arthroplasty rises above $50,000 if the prosthesis is assumed to fail before seven years. Treatment options with ratios above $50,000 per quality-adjusted life year are commonly considered to have limited cost-effectiveness. This threshold is also crossed when the theoretical functional advantages of ankle arthroplasty are eliminated in sensitivity analysis.
The currently available literature has not yet shown that total ankle arthroplasty predictably results in levels of durability and function that make it cost-effective at this time. However, the reference case of this analysis does demonstrate that total ankle arthroplasty has the potential to be a cost-effective alternative to ankle fusion. This reference case assumes that the theoretical functional advantages of ankle arthroplasty over ankle fusion will be borne out in future clinical studies. Performance of total ankle replacement will be better justified if these thresholds are met in published long-term clinical trials.
全踝关节置换术作为终末期踝关节关节炎治疗中踝关节融合术的替代方案,再次引起了人们的关注。尽管缺乏与这些植入物相关的长期临床结果数据,但踝关节置换术的应用仍在不断扩大。本成本效益分析的目的是评估现有文献是否能证明全踝关节置换术的新兴应用是合理的。本研究还确定了踝关节假体耐久性和功能的阈值,若能达到这些阈值,将支持这项新技术更广泛地传播。
创建了一个用于治疗踝关节关节炎的决策模型。回顾文献以确定踝关节融合术和踝关节置换术后可能的结果及其概率。使用效用因子对每个结果进行生活质量加权,并以质量调整生命年为单位表示有效性。根据医疗保险收费和相关代码的报销数据估算总成本。通过敏感性分析评估成本和有效性估计的不确定性影响。
我们模型的参考案例假设假体的生存期限为十年,结果显示踝关节置换术每获得一个质量调整生命年的增量成本效益比为18419美元。这意味着与融合术相比,选择踝关节置换术时,以9578美元的成本可获得0.52个质量调整生命年。该比率与其他医学和外科干预措施的成本效益相比具有优势。敏感性分析确定,如果假设假体在七年之前失效,踝关节置换术每获得一个质量调整生命年的成本将超过50000美元。每质量调整生命年比率高于50000美元的治疗方案通常被认为成本效益有限。当在敏感性分析中消除踝关节置换术的理论功能优势时,也会超过这个阈值。
现有文献尚未表明全踝关节置换术能可预测地产生使其目前具有成本效益的耐久性和功能水平。然而,本分析的参考案例确实表明全踝关节置换术有可能成为踝关节融合术具有成本效益的替代方案。该参考案例假设踝关节置换术相对于踝关节融合术的理论功能优势将在未来的临床研究中得到证实。如果在已发表的长期临床试验中达到这些阈值,全踝关节置换术的应用将更具合理性。